0
0
A CDSCO report revealed that over 40 companies producing cough syrups in the country did not pass quality assessments. This finding was based on lab tests conducted across various states, prompted by reports linking Indian-made cough syrups to 141 child fatalities worldwide.
Among the 1,105 samples tested, 59 were identified as ‘not of standard quality’, according to the report issued by the Central Drugs Standard Control Organisation (CDSCO) in November. These findings were part of a compilation encompassing drugs, medical devices, and cosmetics deemed ‘not of standard quality’, ‘spurious’, ‘adulterated’, or ‘misbranded’. The data was derived from government testing labs, clarifying that no samples were determined as spurious or misbranded.
This scrutiny was instigated following global reports of deaths associated with the consumption of Indian-made cough syrups. In response, the Directorate General of Foreign Trade (DGFT) mandated exporters to obtain government clearance verifying the quality of cough syrups.
Acknowledging the DGFT’s directive, the CDSCO has been rigorously examining all batches of cough syrups seeking export approval.
